Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En studie for å evaluere effektivitet og sikkerhet av intravenøs ACU193 hos deltakere med tidlig Alzheimers sykdom (ALTITUDE-AD) (ALTITUDE-AD)

10. november 2026 oppdatert av: Acumen Pharmaceuticals

En fase 2/3 dobbeltblind, randomisert, placebokontrollert adaptiv designforsøk for å evaluere effektiviteten og sikkerheten til intravenøs ACU193 ved tidlig Alzheimers sykdom

The primary purpose of this study is to evaluate the efficacy of sabirnetug infusions administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's disease.

Studieoversikt

Status

Aktiv, ikke rekrutterende

Studietype

Intervensjonell

Registrering (Faktiske)

542

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • British Columbia
      • Kelowna, British Columbia, Canada
        • Okanagan Clinical Trials
    • Ontario
      • Ottawa, Ontario, Canada
        • Hippocampe d/b/a Ottawa Memory Clinic
      • Toronto, Ontario, Canada
        • Toronto Memory Program (TMP) (Neurology Research Inc.)
    • Quebec
      • Greenfield Park, Quebec, Canada
        • MoCA Research and Innovations
    • California
      • Carlsbad, California, Forente stater, 92011-4219
        • The Neurology Center of Southern California - Carlsbad
      • Fullerton, California, Forente stater, 92835
        • Neurology Center of North Orange County
      • Irvine, California, Forente stater, 92614
        • Irvine Medical Research
      • Long Beach, California, Forente stater, 90804
        • Healthy Brain Research
      • Santa Ana, California, Forente stater, 92705
        • Syrentis Clinical Research
      • Sherman Oaks, California, Forente stater, 91403-2131
        • CenExel - California Neuroscience Research Medical Group, Inc (CNR)
    • Connecticut
      • Norwalk, Connecticut, Forente stater, 06851-4903
        • Research Center for Clinical Studies, LLC
    • District of Columbia
      • Washington D.C., District of Columbia, Forente stater, 22031
        • Re:Cognition Health - Fairfax
    • Florida
      • Atlantis, Florida, Forente stater, 33462
        • JEM Research Institute
      • Bradenton, Florida, Forente stater, 34205
        • Bradenton Research Center
      • Coral Gables, Florida, Forente stater, 33135
        • Gil Fernandez-Yera, MD, PA
      • Delray Beach, Florida, Forente stater, 33445
        • Brain Matters Research
      • Homestead, Florida, Forente stater, 33032
        • Coral Clinical Research
      • Lady Lake, Florida, Forente stater, 32159
        • K2 Medical Research - Villages
      • Miami, Florida, Forente stater, 33126
        • Finlay Medical Research
      • Naples, Florida, Forente stater, 34105-8522
        • Aqualane Clinical Research
      • Ocala, Florida, Forente stater, 34470
        • Ocala Health - Family Care Specialists - Ocala I
      • Port Orange, Florida, Forente stater, 32127
        • Progressive Medical Research
      • Stuart, Florida, Forente stater, 34997
        • Alzheimer's Research and Treatment Center - Stuart
      • Tampa, Florida, Forente stater, 33607
        • K2 Medical Research - Tampa
      • The Villages, Florida, Forente stater, 32162
        • Charter Research - Lady Lake
      • Wellington, Florida, Forente stater, 33414
        • Alzheimers Research and Treatment Center - Wellington
      • Winter Park, Florida, Forente stater, 32789
        • Conquest Research
      • Winter Park, Florida, Forente stater, 32792
        • Charter Research - Winter Park
    • Georgia
      • Columbus, Georgia, Forente stater, 31909
        • Columbus Memory Center
      • Decatur, Georgia, Forente stater, 30030
        • CenExel - iResearch Atlanta
    • Illinois
      • Northbrook, Illinois, Forente stater, 60640
        • Office of Jeffrey S. Ross, MD
    • Massachusetts
      • Newton, Massachusetts, Forente stater, 02459
        • Boston Center for Memory
    • Mississippi
      • Hattiesburg, Mississippi, Forente stater, 39401-7246
        • Hattiesburg Clinic - Memory Center
    • New Hampshire
      • Portsmouth, New Hampshire, Forente stater, 03801
        • ActivMed Practices and Research
    • New Jersey
      • Springfield, New Jersey, Forente stater, 07081
        • The Cognitive and Research Center of New Jersey
      • Toms River, New Jersey, Forente stater, 08755
        • CenExel - Advanced Memory Research Institute of NJ
    • New York
      • Albany, New York, Forente stater, 12208
        • Neurological Associates of Albany
    • North Carolina
      • Matthews, North Carolina, Forente stater, 28105
        • AMC Research
    • Ohio
      • Cleveland, Ohio, Forente stater, 44195
        • Cleveland Clinic
    • Oregon
      • Portland, Oregon, Forente stater, 97210
        • Summit Research Network
    • Pennsylvania
      • Abington, Pennsylvania, Forente stater, 19001
        • Abington Neurological Associates
      • Norristown, Pennsylvania, Forente stater, 19462
        • Keystone Clinical Research
    • Rhode Island
      • East Providence, Rhode Island, Forente stater, 02914
        • Rhode Island Mood and Memory
    • Tennessee
      • Cordova, Tennessee, Forente stater, 38018
        • Neurology Clinic. P.C
      • Knoxville, Tennessee, Forente stater, 37920-1511
        • The Alliance for Multispecialty Research LLC (AMR)
    • Texas
      • Austin, Texas, Forente stater, 78757
        • Senior Adult Specialty Research
      • Beaumont, Texas, Forente stater, 77702
        • Gadolin Research, LLC
      • Dallas, Texas, Forente stater, 75231
        • Kerwin Medical Center
      • Barcelona, Spania
        • Fundacio ACE
      • Donostia / San Sebastian, Spania
        • Policlínica Gipuzkoa
      • Getxo, Spania
        • Cae Oroitu
      • Madrid, Spania
        • Hospital Ruber
      • Seville, Spania
        • Hospital Victoria Eugenia
      • Valencia, Spania
        • Hospital Universitari i Politècnic La Fe
    • Barcelona
      • Sant Cugat del Vallès, Barcelona, Spania
        • Hospital Universitari General de catalunya
    • Zaragoza
      • Cuarte de Huerva, Zaragoza, Spania
        • Fundacion Neuropolis - Hospital Viamed Montecanal
      • Bristol, Storbritannia
        • Re:Cognition Health - Bristol
    • Greater London
      • London, Greater London, Storbritannia
        • Re:Cognition Health - London
      • London, Greater London, Storbritannia
        • St. Pancras Clinical Research Ltd.
    • Hampshire
      • Winchester, Hampshire, Storbritannia
        • Re:Cognition Health - Winchester
    • Lanarkshire
      • Motherwell, Lanarkshire, Storbritannia
        • Neuroclin Glasgow
    • Lancashire
      • Preston, Lancashire, Storbritannia
        • Panthera Bio-Partners - Preston
    • Surrey
      • Guildford, Surrey, Storbritannia
        • Re:Cognition Health - Guildford
    • Yorkshire
      • Sheffield, Yorkshire, Storbritannia
        • Panthera Biopartners - Sheffield
      • Berlin, Tyskland
        • Charité - Universitaetsmedizin Berlin
      • Cologne, Tyskland
        • University Hospital of Cologne
      • Mannheim, Tyskland
        • Zentralinstitut für seelische Gesundheit
      • Munich, Tyskland
        • Technical University of Munich, School of Medicine and Health, Klinikum rechts der Isar

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

50 år til 90 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Body weight of at least 30 kilograms (kg) (66 pounds [lbs]) and no more than 160 kg (352 lbs) at Screening

  • Must consent to apolipoprotein E4 (APOE4) genotype status assessment

  • Must meet all of the following criteria

    1. National Institute on Aging-Alzheimer's Association (NIA-AA) criteria for mild cognitive impairment (MCI) due to Alzheimer's Disease (AD) or probable AD
    2. Screening score between 22 and 30 (inclusive) on the Mini-Mental State Examination (MMSE)
    3. Screening score of 0.5 or 1.0 on the Clinical Dementia Rating Global Score (CDR-GS) and Screening score ≥0.5 on the CDR Memory Box score
    4. Evidence of cerebral amyloid accumulation by either PET scan or CSF
  • If using cholinesterase inhibitors or memantine to treat symptoms related to AD, doses must be stable for at least three months (12 weeks) prior to Baseline and every attempt should be made to keep them at stable doses throughout the study

  • Must have a reliable informant or study partner who is willing and able to perform all the roles as specified in the study partner Informed Consent Form (ICF)

  • Female participants must be surgically sterile or be at least one-year post-menopausal. Male participants with a female partner of child-bearing potential must use adequate contraception

Exclusion Criteria:

  • Has any contraindications for MRI studies, including claustrophobia, the presence of metal (ferromagnetic) implants, or a cardiac pacemaker that is not compatible with MRI

  • MRI of the brain that is inconsistent with MCI or AD or results showing greater than four ARIA-H, presence of any ARIA-E, or superficial siderosis

  • History of significant or unstable neurological disease, other than AD, which may affect cognition or ability to complete the study, such as other dementias, serious infection of the brain, significant head trauma, uncontrolled seizures, stroke, or Parkinson´s disease

  • Current serious or unstable clinically important illness that, in the judgment of the site investigator, is likely to affect cognitive assessment including visual and hearing impairment or affect the participant's safety or ability to complete the study

  • Malignant disease in the last five years except for resected cutaneous squamous cell carcinoma in situ, basal cell carcinoma, cervical carcinoma in situ, or in situ prostate cancer with a normal posttreatment prostate-specific antibody (PSA)

  • Geriatric Depression Scale-Short Form (GDS-SF) score >10 or current symptoms meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V), criteria for major depressive disorder or any current primary psychiatric diagnosis other than AD if, in the judgment of the site investigator, the psychiatric disorder or symptom is likely to confound interpretation of drug effect, affect cognitive assessments, or affect the participant´s ability to complete the study

  • Suicide risk, as determined by meeting any of the following criteria:

    1. Any suicide attempt or preparatory acts/behavior on the C-SSRS Baseline/Screening in the last six months
    2. Suicidal ideation in the last six months as defined by a positive response to Question 5 (Suicidal Ideation) on the C-SSRS Baseline/Screening
    3. Significant risk of suicide, as judged by the site investigator
  • Conditions that may affect cognitive assessments during the study

  • Alcohol use disorder and/or substance use disorder within the last five years

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Double-blind Treatment (DBT) Period: sabirnetug 35 mg/kg

Participants will receive sabirnetug, 35 milligrams per kilogram (mg/kg), Q4W as intravenous (IV) infusion during the DBT period.

Intravenous sabirnetug

Eksperimentell: DBT Period: sabirnetug 50 mg/kg

Participants will receive sabirnetug, 35 mg/kg, for the first two doses, followed by sabirnetug, 50 mg/kg, Q4W as an IV infusion during the DBT period.

Intravenous sabirnetug

Placebo komparator: DBT Period: Placebo

Participants will receive sabirnetug matching placebo, Q4W as an IV infusion during the DBT period.

Intravenous Placebo

Eksperimentell: Open-Label Extension (OLE) Period: sabirnetug 35 mg/kg

Participants will receive sabirnetug, 35 mg/kg, Q4W as an IV infusion during the OLE period.

Intravenous sabirnetug

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change from Baseline in Integrated Alzheimer's Disease Rating Scale (iADRS) Score
Tidsramme: Baseline up to Week 80

iADRS is a validated composite of cognition and function made up of Alzheimer's Disease Assessment Scale - Cognitive Subscale 13-item (ADAS-Cog13) and the Alzheimer's Disease Cooperative Study - instrumental Activities of Daily Living scale (ADCS-iADL). ADAS-Cog13 is a rater-administered instrument consisting of 13 items assessing cognitive function areas most typically impaired in AD. ADAS-Cog13 scores range from 0 to 85, with higher scores indicating a greater deficit of global cognition. The ADCS-iADL is a subset of the 23-item ADCS-ADL (items 6a and 7 to 23). The iADLs are more complex skills required to successfully live independently. iADL-items score ranges from 0 to 59 (lower scores indicating greater impairment). The iADRS is calculated as a linear combination of total scores from the ADAS-Cog13 and ADCS-iADL. The iADRS score ranges from 0 to 144 with lower scores indicating worse performance.

Baseline up to Week 80

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Antall deltakere med behandlingsrelaterte bivirkninger (TEAE)
Tidsramme: Baseline opp til uke 80
Baseline opp til uke 80
Antall deltakere med alvorlige uønskede hendelser (SAE) og uønskede hendelser av spesiell interesse (AESI)
Tidsramme: Baseline opp til uke 80
Baseline opp til uke 80
Antall deltakere som avbryter eller trekker seg på grunn av TEAE
Tidsramme: Baseline opp til uke 80
Baseline opp til uke 80
Antall deltakere med antistoff-antistoffer (ADA) og nøytraliserende antistoffer
Tidsramme: Baseline opp til uke 80
Baseline opp til uke 80
Antall deltakere med amyloidrelatert bildediagnostikk med ødem/effusjoner (ARIA-E) og ARIA med blødning/hemosiderinavsetning (ARIA-H) målt ved magnetisk resonansavbildning (MRI)
Tidsramme: Baseline opp til uke 80
Baseline opp til uke 80
CSF-konsentrasjoner av ACU193 i en undergruppe av deltakere
Tidsramme: Frem til uke 76
Frem til uke 76
Endring fra baseline i amyloid plakkbelastning eller avsetning målt ved positronemisjonstomografi (PET) i centiloider
Tidsramme: Baseline frem til uke 76
Baseline frem til uke 76
Endring fra baseline i volumetrisk magnetisk resonansavbildning (vMRI) av helhjernevolum, ventrikulært volum og volum av utvalgte områder av interesse
Tidsramme: Baseline frem til uke 76
Baseline frem til uke 76
Endring fra baseline i CSF-konsentrasjoner av amyloid, Tau og andre nevrodegenerative biomarkører
Tidsramme: Baseline frem til uke 76
Baseline frem til uke 76
Endring fra baseline i CSF-konsentrasjoner av amyloid, Tau og andre nevrodegenerative biomarkører i en undergruppe av deltakere
Tidsramme: Baseline frem til uke 76
Baseline frem til uke 76
Endring fra baseline i blodkonsentrasjoner av amyloid, Tau og andre nevrodegenerative biomarkører
Tidsramme: Baseline frem til uke 76
Baseline frem til uke 76
Effekt av sabirnetug på klinisk progresjon sammenlignet med placebo vurdert ved bruk av tidssparet analyse målt ved iADRS
Tidsramme: Baseline opp til uke 80
Baseline opp til uke 80
Effekt av sabirnetug på klinisk progresjon sammenlignet med placebo vurdert ved bruk av tidssparet analyse målt med ADCS-iADL
Tidsramme: Baseline opp til uke 80
Baseline opp til uke 80
Effekt av sabirnetug på klinisk progresjon sammenlignet med placebo vurdert ved bruk av tidssparet analyse målt med ADAS-Cog13
Tidsramme: Baseline opp til uke 80
Baseline opp til uke 80
Effekt av sabirnetug på klinisk progresjon sammenlignet med placebo vurdert ved bruk av tidssparet analyse målt ved CDR-SB
Tidsramme: Baseline opp til uke 80
Baseline opp til uke 80
Effekt av sabirnetug på klinisk progresjon sammenlignet med placebo vurdert ved bruk av tidssparet analyse målt ved MMSE
Tidsramme: Baseline opp til uke 80
Baseline opp til uke 80
Serum Konsentrasjon av sabirnetug
Tidsramme: Før dose og flere tidspunkter etter dose opp til 80 uker
Før dose og flere tidspunkter etter dose opp til 80 uker
Konsentrasjon av sabirnetug i cerebrospinalvæske (CSF)
Tidsramme: Frem til uke 76
Frem til uke 76
Målengasjement vurdert ved måling av sabirnetug-amyloid-β oligomer (AβO) kompleks i CSF
Tidsramme: Frem til uke 76
Frem til uke 76
Change from Baseline in ADCS-iADL Score
Tidsramme: Baseline up to Week 80

The ADCS-ADL is a 23-item inventory developed as a rater-administered questionnaire to be answered by a participant's study partner, where a participant's performance level is rated over the last 4 weeks, based on a set of performance descriptions. The ADCS-iADL is a subset of the 23-item ADCS-ADL (items 6a and 7 to 23). The iADLs are more complex skills required to successfully live independently, and include shopping, keeping appointments, traveling outside of the home, making a meal or snack, and reading and writing. The iADL-items score ranges from 0 to 59 with lower scores indicating greater impairment.

Baseline up to Week 80
Change from Baseline in ADAS-Cog13 Score
Tidsramme: Baseline up to Week 80

ADAS-Cog is a rater-administered instrument, designed to assess the severity of dysfunction in cognition, characteristic of persons with AD. The ADAS-Cog13, the cognitive subscale of the ADAS, consists of 13 items assessing cognitive function areas most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, and digit cancellation. The scores range from 0 to 85, with higher scores indicating a greater deficit of global cognition.

Baseline up to Week 80
Change from Baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB)
Tidsramme: Baseline up to Week 80

The CDR is obtained through semi-structured interviews of individuals with AD and informants. The ratings are obtained in six domains: memory, orientation, judgment & problem-solving, community affairs, home & hobbies, and personal care. Each domain is rated on a five-point scale of functioning as follows: 0 = no impairment; 0.5 = questionable impairment; 1 = mild impairment; 2 = moderate impairment; and 3 = severe impairment. CDR-SB score is obtained by summing each of the domain scores, with scores ranging from 0 to 18. Higher scores reflect greater cognitive and functional impairment.

Baseline up to Week 80
Change from Baseline in Mini-Mental State Examination (MMSE)
Tidsramme: Baseline up to Week 80

MMSE is a standard staging and assessment tool in AD, designed for grading the cognitive state of individuals with AD. The scale comprises tasks concerning orientation, memory, attention, language, and praxis to evaluate an individual's cognitive state. MMSE total score ranges from 0 to 30, with lower scores indicative of greater cognitive impairment.

Baseline up to Week 80
Change from Baseline in Quality of Life in Alzheimer's Disease (QoL-AD)
Tidsramme: Baseline up to Week 80

The QOL-AD tool is a 13-item assessment with each question scored on a 4-point scale where 1 = poor quality of life and 4 = excellent quality of life. Scores range from 13 to 52 with higher scores indicating better quality of life.

Baseline up to Week 80
Change from Baseline in Neuropsychiatric Inventory Questionnaire (NPI-Q) Score
Tidsramme: Baseline up to Week 80

NPI-Q is a validated questionnaire completed by informants about participants for whom they care. Each of the 12 NPI-Q domains contains a survey question (answered in Yes/No) that reflects the cardinal symptoms of that domain. If the domain response is "Yes," the informant then rates the severity of the symptoms present within the last month on a 3-point scale and the distress of the symptom using a 5-point scale. The total NPI-Q severity score is the sum of the individual severity scores for each symptom and ranges from 0 to 36, with higher scores indicating more severe behavioral impairment. The total NPI-Q distress score is the sum of the individual distress scores for each symptom and ranges from 0 to 60, with higher scores indicating greater caregiver distress.

Baseline up to Week 80
Change from Baseline in EuroQoL 5-Dimension 5-Level (EQ-5D-5L)
Tidsramme: Baseline up to Week 80

EQ-5D-5L is a self-report survey that measures quality of life. The EQ-5D-5L consists of an EQ-5D descriptive system and EQ visual analog scale (EQ VAS). The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has five levels, each assigned a unique 1-digit number: no problems, slight problems, moderate problems, severe problems, and extreme problems. The digits are combined into a 5-digit number that describes the participant's health state. The EQ VAS records the participant's health on a vertical visual analog scale, where the endpoints are labeled 0= the best health you can imagine, and 100= the worst health you can imagine.

Baseline up to Week 80
Change from Baseline in Resource Utilization in Dementia (RUD)
Tidsramme: Baseline up to Week 80

The RUD questionnaire is a standardized tool and the most widely used instrument for resource use data collection in dementia, enabling comparison of costs of care across countries with differing health care provisions. It is designed to collect data on formal and informal care resource use and to be useful in different care settings, across different countries and care systems, and in both clinical studies and observational cost-of-illness studies.

Baseline up to Week 80
Change from Baseline in Zarit Burden Interview (ZBI)
Tidsramme: Baseline up to Week 80

ZBI consists of 22 items. Twenty-one of the items are designed to measure several aspects of burden, whereas Item 22 is a global measure of burden. Response options for each item range from 0-4, and total scores range from 0-88, with higher scores indicating greater self-reported burden.

Baseline up to Week 80
Percentage of Participants with No Clinical Progression at One Year
Tidsramme: Baseline up to Week 80

No clinical progression in participants will be defined as no decline in CDR-SB score. The CDR is obtained through semi-structured interviews of individuals with AD and informants. The ratings are obtained in six domains: memory, orientation, judgment & problem-solving, community affairs, home & hobbies, and personal care. Each domain is rated on a five-point scale of functioning as follows: 0 = no impairment; 0.5 = questionable impairment; 1 = mild impairment; 2 = moderate impairment; and 3 = severe impairment. CDR-SB score is obtained by summing each of the domain scores, with scores ranging from 0 to 18. Higher scores reflect greater cognitive and functional impairment.

Baseline up to Week 80
Number of Participants with Suicidal Ideation and Behavior as Measured by Columbia-Suicide Severity Rating Scale (C-SSRS)
Tidsramme: Baseline up to Week 80

The C-SSRS includes 'yes' or 'no' responses for assessment of suicidal ideation and behavior as well as numeric ratings for severity of ideation, if present (from 1 to 5, with 5 being the most severe). Greater lethality or potential lethality of suicidal behaviors (endorsed on the behavior subscale) indicates increased risk.

Baseline up to Week 80
Correlation Between sabirnetug Exposure with Clinical Efficacy Measures
Tidsramme: Baseline up to 80 weeks

Correlation between sabirnetug exposure and clinical outcomes (including iADRS, CDR-SB, ADCS-iADL, ADAS-Cog13, and MMSE) will be assessed in this study.

Baseline up to 80 weeks
Correlation Between Change in Biomarker that Reflect Disease Progression and Clinical Changes
Tidsramme: Up to 80 weeks

Assessment of the correlation between change in clinical outcomes (iADRS, CDR-SB, ADCS-iADL, ADAS-Cog13, and MMSE) and change in biomarker (amyloid PET) will be determined by computing Pearson's correlation coefficient for each treatment group.

Up to 80 weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

29. februar 2024

Primær fullføring (Faktiske)

29. oktober 2026

Studiet fullført (Antatt)

1. desember 2026

Datoer for studieregistrering

Først innsendt

13. mars 2024

Først innsendt som oppfylte QC-kriteriene

21. mars 2024

Først lagt ut (Faktiske)

28. mars 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

12. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

10. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere